PSMA & Beyond is one of the most focused meetings in the theranostics space — dedicated entirely to PSMA-targeted imaging and therapy. The program covers clinical trial updates, real-world implementation, and brings together the researchers and clinicians shaping the future of PSMA theranostics. Nucs AI is a Silver Sponsor of the event, with a dedicated table for live demonstrations of our AI-powered PSMA-PET/CT analysis tools.

‍

It was a valuable time at PSMA and Beyond 2026— hosted by UCLA, UCSF, and the Prostate Cancer Foundation.Two days with the physicians and researchers shaping the future of PSMA-targeted theranostics. Topics spanned:- PCWG4 response criteria and PSMA-PET/CT integration into trial design- Whole-body PET quantification and reporting standardization- Clinical trial updates — PSMAddition, PEACE-3, STAMPEDE2, and more- Combination strategies — RLT with PARP inhibitors, immunotherapy, and alpha emitters- Next-gen radionuclides — Ac-225 and Astatine-211- Emerging targets beyond PSMA — PSCA, STEAP1, DLL3, and othersTwo themes stood out to us: PSMA-PET/CT reporting standardization is gaining real momentum — structured templates, quantitative metrics, and reader confidence scoring are moving from proposal to practice. And whole-body tumor volume and SUVmean continue to prove prognostic across disease stages, reinforcing why automated quantification matters. If we didn't get a chance to meet, let's keep the conversation going.

‍